SYN News and Press, Synthetic Biologics Inc. From 08/10/22

Synthetic Biologics ( NYSE: SYN ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.30 (-1400.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 ...

Major earnings expected before the bell on Thursday include: Arrival ( ARVL ) Brookfield Asset Management ( BAM ) Cardinal Health ( CAH ) Hanesbrands ( HBI ) Himax Technologies ( HIMX ) For further details see: Notable earnings before Thur...

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s management will participate in one...

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, Aug...

ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today ...

Enveric Biosciences ( ENVB ) -20% announces $8M registered direct offering and private placement, priced at a premium to market under Nasdaq rules. Squarespace ( SQSP ) -13% on Q2 results. Baosheng Media Group Holdings ( BAOS ) -12% . Addex ...

Synthetic Biologics ( NYSE: SYN ) shares dropped around 14% pre-market after the therapeutics company announced plans for a reverse stock split of its issued and outstanding common stock. Effective July 25, 2022, each ten (10) pre-split shares of common stock outstanding w...

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding comm...

Synthetic Biologics, Inc. (SYN) Q1 2022 Earnings Conference Call May 16, 2022, 09:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and CFO Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Jim Molloy - All...

Synthetic Biologics press release (NYSE:SYN): Q1 GAAP EPS of -$0.03 in-line. As of March 31, 2022, the company reported $56.7M in cash, which is expected to provide runway through the end of 2023. For further details see: Synthetic Biologics GAAP EPS of -$0.03 in-line